全球智库信息集成服务系统

Key Findings:

• Expanding HCV screening in the IHS service population to include all women of reproductive age or universal screening for all individuals ages 15–64 would be cost-beneficial in the long term at a seroprevalence of 0.20 percent or above. Studies estimate seroprevalence in AI/AN populations to be higher than 0.20 percent, ranging from 0.82 percent to11.5 percent (McMahon et al. 2004; Mera et al. 2016; Neumeister et al. 2007).
• The model to identify the seroprevalence threshold at which expanded screening becomes cost-beneficial is highly sensitive to the cost of the drugs used to treat HCV. If more expensive drugs are used, the seroprevalence at which screening becomes cost-beneficial rises to as much as 10.0 percent. Given the range of seroprevalence estimates for AI/AN populations, it is likely that expanded screening would be cost-beneficial even if more expensive drugs are used, but expanded screening is unlikely to be cost-beneficial if the majority of HCV-positive patients receive the most expensive drug regimens currently available.